Sign In
Buy NYXH
$2.87
-0.100 (-3.37%)
At Close: Jun 03, 2026
Nyxoah Announces Proposed Offering of Ordinary Shares
04:05pm, Wednesday, 22'nd May 2024
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Na
HC Wainwright Research Analysts Cut Earnings Estimates for Nyxoah S.A. (NASDAQ:NYXH)
01:38am, Monday, 20'th May 2024
Nyxoah S.A. (NASDAQ:NYXH – Free Report) – Investment analysts at HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for shares of Nyxoah in a report released on Wednesd
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
04:30pm, Monday, 13'th May 2024
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah�
Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024
01:00am, Friday, 10'th May 2024
REGULATED INFORMATION May 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to atten
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
04:30pm, Thursday, 11'th Apr 2024
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation First medical device company to become a corporate champi
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
04:05pm, Tuesday, 19'th Mar 2024
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002) Reports an Oxygen Desaturati
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
07:01pm, Tuesday, 05'th Mar 2024
Nyxoah SA (NYXH) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.52 per share a year ago.
Nyxoah S.A. (NYXH) Q4 2023 Earnings Call Transcript
06:49pm, Tuesday, 05'th Mar 2024
Nyxoah S.A. (NYXH) Q4 2023 Earnings Call Transcript
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
04:05pm, Tuesday, 05'th Mar 2024
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results Expect to report DREAM U.S. pivotal study efficacy and safety data by early April Achieved record quarterly sales
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
04:30pm, Thursday, 29'th Feb 2024
Nyxoah to Participate in the Oppenheimer 34 th Annual Healthcare MedTech & Services Conference
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
04:30pm, Thursday, 15'th Feb 2024
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/
Nyxoah Announces 2024 Strategic Priorities
04:05pm, Wednesday, 17'th Jan 2024
Nyxoah Announces 2024 Strategic Priorities Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”),
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
04:05pm, Tuesday, 09'th Jan 2024
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®
01:30am, Monday, 11'th Dec 2023
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8,
